Trial Profile

A Phase 1B Trial To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of CVL-231 in Subjects With Schizophrenia

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emraclidine (Primary)
Indications Schizophrenia
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
Sponsors Cerevel Therapeutics

Most Recent Events

15 Dec 2022 According to a Cerevel Therapeutics media release, data from the study were announced at the conferences including the American College of Neuropsychopharmacology 2021 and the Neuroscience Education Institute Congress 2022.
15 Dec 2022 Results published in the Cerevel Therapeutics Media Release.
15 Dec 2022 According to a Cerevel Therapeutics media release, data from the study was published in The Lancet.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com